| Name | Title | Contact Details |
|---|
Avaxia is a leader in the growing field of gut-targeted therapeutics — orally administered, minimally absorbed drugs that are designed to act locally in the gastrointestinal tract. Avaxia’s lead clinical candidate, AVX-470, is an oral anti-TNF antibody for inflammatory bowel disease. This transformative product offers potentially improved safety and efficacy over existing anti-TNF therapies by focusing immune suppression only where needed in the diseased gut. Avaxia plans to use its gut-targeted antibody platform to develop therapeutics to address many other serious diseases such as type 2 diabetes, celiac disease, GI acute radiation syndrome and oral mucositis.
Columbia Laboratories is a specialty pharmaceutical company that develops and commercializes innovative products for women’s healthcare and endocrine-related conditions. Our FDA-approved products include formulations that treat infertility, menstrual irregularities and hormonal deficiencies. Columbia’s products utilize our proprietary Bioadhesive Delivery System (BDS), which leverages the principle of bioadhesion to administer medication. This technology can deliver many types of compounds, including hormones and peptides, providing numerous internal and licensing product development opportunities.
Genome Quebec Pharmacogenomics Centre is a MontríŠal, QC-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Harlan, Heather is a Glen Burnie, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Protech Home Medical is a rapidly growing leader in the provision of clinical respiratory equipment and service to patients.